bioMerieux (OTCMKTS:BMXMF) Shares Gap Down – Time to Sell?

bioMerieux (OTCMKTS:BMXMF)’s share price gapped down before the market opened on Friday. The stock had previously closed at $88.6650, but opened at $84.06. bioMerieux shares last traded at $85.00, with a volume of 2,000 shares.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. Morgan Stanley reaffirmed an “underweight” rating on shares of bioMerieux in a report on Friday, September 11th. Zacks Research raised bioMerieux from a “strong sell” rating to a “hold” rating in a report on Monday. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of bioMerieux in a report on Wednesday, June 17th. Finally, Piper Sandler initiated coverage on bioMerieux in a research report on Thursday, June 11th. They issued a “neutral” rating on the stock. Five investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, bioMerieux has an average rating of “Reduce”.

bioMerieux Stock Performance

The business’s 50 day simple moving average is $83.27 and its two-hundred day simple moving average is $87.43.

About bioMerieux

bioMérieux is a France-based healthcare company specializing in in vitro diagnostics. The company develops, manufactures and markets diagnostic systems, reagents and software used to detect infectious diseases, support antimicrobial therapy decisions and assist with disease management.

Its product portfolio includes solutions for microbiology, molecular biology, immunoassays and syndromic testing. bioMérieux’s systems are used by hospitals, clinical laboratories and healthcare providers, while its industrial applications serve the food, pharmaceutical and cosmetics industries by helping customers monitor contamination, quality and safety.

Founded in 1963 by Alain Mérieux, bioMérieux traces its heritage to the Mérieux family’s work in medical diagnostics.